OSCR
Oscar Health, Inc.
OSCR has the edge over SPOK overall, supported by stronger fundamentals and stronger modeled upside.
SPOK
Spok Holdings, Inc.
SPOK has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SPOK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Strong |
SPOK's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over SPOK in the historical PE scenario, which offers more potential upside but is not a forecast.
SPOK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.6x | $7.56 | -35% |
| Current | 13x | $11.62 | — |
| Fair | 18x | $15.91 | +37% |
| Expensive | 22x | $19.16 | +65% |
Historical ranges are pointers, not guarantees.
SPOK's PE is in its cheap range at 13x.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SPOK Forward outlook
There aren't enough analyst estimates for SPOK to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
SPOK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.88 | +11% |
| Q2 2026 | $0.57 | -30% |
| Q1 2026 | $0.59 | -23% |
| Q4 2025 | $0.75 | +2.7% |
| Q3 2025 | $0.79 | +8.2% |
| Q2 2025 | $0.82 | +6.5% |
| Q1 2025 | $0.77 | -7.2% |
| Q4 2024 | $0.73 | -5.2% |
SPOK's earnings per share have fallen from their peak: $0.88 over the past year, against $1.81 in late 2023.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SPOK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
SPOK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $33M | -2.6% |
| Q2 2026 | $35M | -1.9% |
| Q1 2026 | $33.2M | -8.5% |
| Q4 2025 | $33.9M | -0.1% |
| Q3 2025 | $33.9M | -2.9% |
| Q2 2025 | $35.7M | +5% |
| Q1 2025 | $36.3M | +4% |
| Q4 2024 | $33.9M | -0.2% |
SPOK's revenue fell from its 2019 peak and has held roughly level since: $33M last quarter, down 2.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 17% | +4.2 points |
| Q2 2026 | 16% | +0.4 points |
| Q1 2026 | 7.4% | -9.2 points |
| Q4 2025 | 12% | -2 points |
| Q3 2025 | 13% | -1.4 points |
| Q2 2025 | 15% | +1.9 points |
| Q1 2025 | 17% | +2.6 points |
| Q4 2024 | 14% | +1.7 points |
SPOK has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over SPOK on cash flow, with more consistent year-over-year improvement.
SPOK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $12.2M | +62% |
| Q2 2026 | $5.9M | -2% |
| Q1 2026 | $1.8M | +22% |
| Q4 2025 | $10.1M | +34% |
| Q3 2025 | $7.6M | -26% |
| Q2 2025 | $6M | -12% |
| Q1 2025 | $1.5M | +34% |
| Q4 2024 | $7.5M | -30% |
SPOK generated $30M in free cash flow over the past year, up 33% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SPOK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +128K shares |
| 1 year | +0.9% | +184K shares |
| 3 years | +4.5% | +909K shares |
| 5 years | +9% | +1.7M shares |
| Available history | +11% | +2.1M shares |
SPOK has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over SPOK on leverage, with a lower net debt burden relative to earnings.
SPOK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.4x | Net Cash |
| Q2 2026 | -0.8x | Net Cash |
| Q1 2026 | -0.9x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -0.9x | Net Cash |
| Q2 2025 | -0.8x | Net Cash |
| Q1 2025 | -0.8x | Net Cash |
| Q4 2024 | -1.3x | Net Cash |
SPOK has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SPOK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.2 | Neutral |
| Stochastic | 76.0 | Neutral |
SPOK's weekly RSI is 55 (neutral) and its Stochastic is 76 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over SPOK on valuation relative to its sector.
SPOK PE vs Healthcare Sector
| Metric | SPOK | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 49% below |
| PE % | 27 | 29 | 2 pts below |
SPOK is trading at 13x earnings, a 49% discount to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SPOK on trend strength, trading above more of its moving averages.
SPOK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.0 | 5.3% above |
| 20 week MA | $10.8 | 7.3% above |
| 50 week MA | $11.5 | 0.9% above |
| 100 week MA | $13.9 | 17% below |
| 200 week MA | $14.1 | 17% below |
SPOK has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 17% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SPOK on returns for 2026, with the stronger performance.
SPOK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.1 | $11.0 | -9% |
| 2021 | $11.0 | $8.72 | -21% |
| 2022 | $8.72 | $8.24 | -5.5% |
| 2023 | $8.24 | $15.5 | +88% |
| 2024 | $15.5 | $16.2 | +4.8% |
| 2025 | $16.2 | $13.0 | -20% |
| 2026 YTD | $13.0 | $11.6 | -10% |
SPOK has finished lower in four of the last six years. It's down 10% so far in 2026.